Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest.

Gargiulo, Giuseppe; Valgimigli, Marco; Sunnaker, Mikael; Vranckx, Pascal; Frigoli, Enrico; Leonardi, Sergio; Spirito, Alessandro; Gragnano, Felice; Manavifar, Negar; Galea, Roberto; De Caterina, Alberto R; Calabrò, Paolo; Esposito, Giovanni; Windecker, Stephan; Hunziker Munsch, Lukas (2020). Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. Revista española de cardiología (English ed.), 73(11), pp. 893-901. Elsevier 10.1016/j.rec.2020.01.005

[img] Text
Gargiulo_RevEspCardiol_EnglEd__2020.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (399kB) | Request a copy


Patients who are vulnerable to hemodynamic or electrical disorders (VP) are often excluded from clinical trials and data on the optimal access-site or antithrombotic treatment are limited. We assessed outcomes of transradial vs transfemoral access and bivalirudin vs unfractionated heparin (UFH) in VP with acute coronary syndrome undergoing invasive management.


The MATRIX trial randomized 8404 patients to radial or femoral access and 7213 patients to bivalirudin or UFH. Among them, 934 (11.1%) were deemed VP due to advanced Killip class (n = 808), cardiac arrest (n = 168), or both (n = 42). The 30-day coprimary outcomes were major adverse cardiovascular and cerebrovascular events (MACE: death, myocardial infarction, or stroke) and net adverse clinical events (NACE: MACE or major bleeding).


MACE and NACE were similarly reduced with radial vs femoral access in VP and non-VP. Transradial access was also associated with consistent relative benefits in all-cause and cardiovascular mortality or Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding with greater absolute benefits in VP. The effects of bivalirudin vs UFH on MACE and NACE were consistent in VP and non-VP. Bivalirudin was associated with lower all-cause and cardiovascular mortality in VP but not in non-VP, with borderline interaction testing. Bivalirudin reduced bleeding in both VP and non-VP with a larger absolute benefit in VP.


In acute coronary syndrome patients undergoing invasive management, the effects of randomized treatments were consistent in VP and non-VP, but absolute risk reduction with radial access and bivalirudin were greater in VP, with a 5- to 10-fold lower number needed to treat for benefits. Trial registry number: NCT01433627.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Pre-clinic Human Medicine > Department of Clinical Research (DCR)

UniBE Contributor:

Gargiulo, Giuseppe, Valgimigli, Marco, Sunnaker, Mikael Anders, Frigoli, Enrico, Spirito, Alessandro, Manavifar, Negar, Galea, Roberto, Windecker, Stephan, Hunziker Munsch, Lukas Christoph


600 Technology > 610 Medicine & health








Andrea Flükiger-Flückiger

Date Deposited:

18 Mar 2020 12:40

Last Modified:

20 Feb 2024 14:16

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

Acceso radial Acute coronary syndrome Acute heart failure Bivalirudin Bivalirudina Cardiac arrest Insuficiencia cardiaca aguda Paciente vulnerable Parada cardiaca Radial access Síndrome coronario agudo Vulnerable patients




Actions (login required)

Edit item Edit item
Provide Feedback